Jazz Pharmaceuticals financials
$232.35−2.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B |
| Gross profit | $3.76B | $3.62B | $3.40B | $3.12B | $2.65B | $2.21B | $2.03B | $1.77B | $1.51B | $1.38B |
| Gross margin | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M | $378.1M | $532.4M | $614.8M | $528.8M | $591.7M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M | $238.6M | $523.4M | $447.1M | $487.8M | $396.8M |
| Net margin | −8.3% | 13.8% | 10.8% | −6.1% | −10.7% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% |
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 |
| EBITDA | $1.21B | $1.39B | $1.24B | $1.14B | $722.8M | $1.04B | $1.01B | $874.5M | $779.0M | $729.2M |
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.5M | $899.6M | $776.4M | $798.9M | $693.1M | $592.4M |
| Free cash flow | $1.30B | $1.36B | $1.07B | $798.8M | $750.9M | $884.6M | $736.3M | $778.5M | $664.1M | $582.7M |
| Diluted shares | 61.0M | 66.0M | 72.1M | 62.5M | 59.7M | 56.5M | 57.6M | 61.2M | 61.3M | 61.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.39B | $2.41B | $1.51B | $881.5M | $591.4M | $1.06B |
| Short-term investments | $1.05B | $580.0M | $120.0M | $0.00 | — | $1.07B |
| Total debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B |
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B |
| Total liabilities | $7.34B | $7.92B | $7.66B | $7.75B | $8.33B | $2.88B |
| Shareholders' equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology